$61.91
1.89% yesterday
Nasdaq, Sep 08, 10:00 pm CET
ISIN
US36870G1058
Symbol
IRON

Gemini Therapeutics Inc Stock price

$61.91
+3.88 6.69% 1M
+8.54 16.00% 6M
-1.49 2.35% YTD
+10.17 19.66% 1Y
+47.31 324.04% 3Y
-42.59 40.76% 5Y
-41.09 39.89% 10Y
-41.09 39.89% 20Y
Nasdaq, Closing price Mon, Sep 08 2025
+1.15 1.89%
ISIN
US36870G1058
Symbol
IRON
Industry

Key metrics

Basic
Market capitalization
$2.1b
Enterprise Value
$1.5b
Net debt
positive
Cash
$650.0m
Shares outstanding
34.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
3.4
Financial Health
Equity Ratio
89.3%
Return on Equity
-24.6%
ROCE
-26.2%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-168.6m | $-195.3m
EBIT
$-168.8m | $-215.2m
Net Income
$-145.4m | $-198.3m
Free Cash Flow
$-135.6m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-52.2% | -50.8%
EBIT
-52.1% | -65.9%
Net Income
-59.8% | -81.3%
Free Cash Flow
-82.3%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-4.2
FCF per Share
$-3.9
Short interest
7.8%
Employees
125
Rev per Employee
$0.0
Show more

Is Gemini Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,009 stocks worldwide.

Gemini Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Gemini Therapeutics Inc forecast:

17x Buy
94%
1x Hold
6%

Analyst Opinions

18 Analysts have issued a Gemini Therapeutics Inc forecast:

Buy
94%
Hold
6%

Financial data from Gemini Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 45 45
69% 69%
-
- Research and Development Expense 124 124
47% 47%
-
-169 -169
52% 52%
-
- Depreciation and Amortization 0.13 0.13
32% 32%
-
EBIT (Operating Income) EBIT -169 -169
52% 52%
-
Net Profit -145 -145
60% 60%
-

In millions USD.

Don't miss a Thing! We will send you all news about Gemini Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Gemini Therapeutics Inc Stock News

Positive
The Motley Fool
about one month ago
Disc Medicine (IRON -1.79%), a clinical-stage biopharmaceutical company advancing treatments for hematologic diseases, released its second quarter 2025 earnings on August 7, 2025. Reflecting investments in critical clinical programs, the period showed progress on pipeline milestones but highlighted accelerating losses associated with ramping up for late-stage trials and potential commercializat...
Neutral
GlobeNewsWire
about 2 months ago
WATERTOWN, Mass., July 14, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Nadim Ahmed to its Board of Directors. Mr. Ahmed is currently the President and Chief Executi...
Neutral
GlobeNewsWire
3 months ago
WATERTOWN, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today spotlights 5 posters presented at the EHA 2025 annual meeting in Milan, Italy. This year's presentations included data fro...
More Gemini Therapeutics Inc News

Company Profile

Gemini Therapeutics, Inc. is a clinical-stage precision medicine company. It is developing novel therapeutic compounds to treat genetically defined, age-related macular degeneration. The company was founded by Johanna Seddon, Paul Barlow and Andrew Herbert on March 3, 2015 and is headquartered in Cambridge, MA.

Head office United States
CEO John Quisel
Employees 125
Founded 2017
Website www.discmedicine.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today